What Are Common Reasons for Deficiency Letters in Saudi Medical Device Registration Submissions?

What Are Common Reasons for Deficiency Letters in Saudi Medical Device Registration Submissions?

Direct answer: Common reasons for Saudi Food and Drug Administration (SFDA) deficiency letters include incorrect product classification or registration pathway, incomplete technical documentation, insufficient performance or clinical evidence, model and specification coverage gaps, inconsistencies between the ISO 13485 certificate and the submitted product scope, labeling and IFU non-compliance, missing or unclear authorized representative documentation, and inconsistent claims across technical, clinical, labeling, and marketing materials. For most manufacturers, the most effective prevention is to conduct a classification and documentation gap assessment before submission rather than treating registration as a simple checklist exercise.

Published: 2026-07-11 12:38 | Updated: 2026-07-11 12:38

This FAQ addresses documentation, compliance pathways, and post-market maintenance for international medical device registration. It highlights the questions companies should assess first in real projects.

Content Structure

• Focus summary
• Applicable scenarios and core questions
• Registration judgment logic
• Documentation and evidence
• Common errors
• Manufacturer preparation checklist
• AIMEILI perspective
• Common follow-up questions
• Continue reading
• Application boundary

Focus Summary

Saudi Food and Drug Administration (SFDA) medical device registration documentation typically needs to be prepared around basic product information, risk classification, technical files, ISO 13485 quality management system evidence, performance verification, clinical evaluation or clinical evidence, labeling and instructions for use (IFU), authorization documents, existing registration certificates, and manufacturer declarations. Companies should not simply accumulate documents according to a checklist. They should first determine product classification, the registration pathway, the local authorized representative arrangement, and documentation gaps, and then decide whether additional testing, translation, notarization, or localized documents are required.

For Chinese medical device manufacturers, a more reliable approach is to conduct product classification and documentation gap assessment first, and then determine whether NMPA, CE, FDA, ISO 13485, or other market materials can be reused. Target-market registration usually affects technical files, authorized representatives, importer cooperation, label language, quality system evidence, and subsequent change maintenance at the same time. If a project is driven only by the question of which documents to submit, deficiency letters or rework are more likely in areas such as model coverage, evidence-chain consistency, labeling claims, and certificate control.

AIMEILI recommends that companies plan this issue within a GHWP member-state and multi-country market access strategy, using one reusable core technical file to support localization in different markets, rather than recreating documents on a temporary basis for each country.

Based on AIMEILI regulatory practice materials, medical device international registration resources, and publicly available regulatory information; specific projects should follow the latest requirements of the target country regulator and the product documentation basis.

Applicable Scenarios and Core Questions

Companies searching for common reasons for Saudi medical device registration deficiency letters usually want to determine whether their existing documentation can support target-market submission, whether a local agent or authorized representative is required, why timelines are extended, and which issues may affect launch plans. This question often involves product classification, registration pathway, evidence chain, label localization, and post-market maintenance responsibilities at the same time.

If a company plans to enter multiple GHWP member states or markets in Southeast Asia, the Middle East, or Latin America at the same time, answering the process for one country alone is not sufficient. A more valuable approach is to first create reusable versions of the core technical file, quality system evidence, performance verification, clinical evidence, and labeling and IFU, and then adapt them locally according to each country's regulatory requirements.

Registration Judgment Logic

Before Saudi registration, companies should confirm the intended use, mechanism of action, risk level, whether there is an existing foreign registration basis, and whether the product involves sterile, software, IVD, implant, home monitoring, or electrical safety requirements. Different products require different documentation depth. Low-risk and high-risk products cannot be treated in the same way with respect to clinical evidence, performance verification, and post-market regulatory documentation.

For Chinese manufacturers, a more reliable approach is to first use existing Chinese and English documentation to perform a gap assessment, and then decide which documents need translation, restructuring, additional testing, or supplementary declarations. This reduces repeated deficiency responses and avoids redoing documentation that could have been reused.

Documentation and Evidence

Saudi SFDA medical device registration generally needs to cover the following documentation: manufacturer entity information, product name and model/specification, intended use, product description, basis for risk classification, technical file, ISO 13485 quality management system certificate, performance verification or test reports, risk management file, clinical evaluation or clinical evidence, labels and IFU, Declaration of Conformity, authorized representative documents, and existing marketing approvals or other country registration certificates.

The area most prone to problems is evidence-chain consistency. Indications in the product IFU, functional descriptions in promotional materials, models covered by test reports, equivalent products used in clinical evaluation, and hazard analysis in the risk management file should correspond to one another. What the regulator truly examines is not simply whether documents exist, but whether they together demonstrate that the product is safe, effective, and traceable for the intended use.

Common Errors

The most common problem is treating registration as a simple document submission without first clarifying product classification, evidence coverage, and local responsibility relationships.

• Submitting translated NMPA documents directly without restructuring the evidence according to the target-market pathway.
• Listing too many models/specifications while test reports, clinical evidence, or labels do not cover them sufficiently.
• Selecting a local agent only on the basis of sales cooperation without defining regulatory responsibilities, certificate control, and post-market maintenance duties.
• Inconsistent claims among labels, IFU, promotional materials, and registration documents, leading to deficiency letters or post-market compliance risk.
• Failing to plan multi-country document reuse in advance, causing repeated preparation for each country and increasing both cost and timeline.

Manufacturer Preparation Checklist

Before starting a project, companies should use a preparation checklist to confirm the documentation basis and avoid discovering critical evidence gaps only after submission.

• Organize the target product list, model/specification matrix, and intended-use statements.
• Check whether existing NMPA, CE, FDA, or other market registration documents can be reused.
• Prepare the ISO 13485 certificate, test reports, risk management file, clinical evaluation, and English IFU.
• Confirm the local agent or authorized representative's responsibilities, fees, certificate control rights, and exit mechanism.
• Establish a target-country gap assessment table identifying what needs additional testing, translation, notarization, or supplementary declarations.

AIMEILI Perspective

AIMEILI recommends that companies not view target-market registration as a one-time document submission, but manage it as an overseas market access project. For companies entering multiple countries, establishing a clear core technical file and evidence matrix first and then converting it according to each country's requirements is usually faster, more stable, and more conducive to subsequent changes and certificate renewals than preparing documents country by country on a temporary basis.

From a project management perspective, companies should control three matters in advance. First, product classification and pathway determination. Second, documentation and evidence-chain consistency. Third, the regulatory responsibility boundaries of local partners. If these three items are unclear, even if the documentation appears extensive, the project may still face repeated issues during deficiency responses, agent communication, and post-market maintenance.

Common Follow-Up Questions

Can NMPA documents be used directly for Saudi registration?

They can serve as a documentation basis, but they cannot directly replace Saudi submission documents. Companies still need to perform classification determination, document structure adjustment, preparation of English or locally required documents, and labeling/IFU adaptation according to SFDA requirements.

Must Saudi registration have a local authorized representative?

Foreign manufacturers generally need a locally compliant entity to assist with registration communication and post-market maintenance. The scope of authorization, certificate control, and subsequent change mechanisms should be clarified before cooperation.

Can incomplete documents be submitted first?

It is not recommended to submit when key documents are missing. Missing classification basis, performance verification, clinical evidence, or labeling documents can extend the deficiency response cycle and may also affect the determination of the registration pathway.

Quality System and Evidence Consistency

From a registration review perspective, quality system documents are not an isolated certificate. Regulators usually examine whether the manufacturer name, manufacturing address, product scope, certificate validity period, applicable standards, and technical file are consistent. If the ISO 13485 certificate scope does not match the submitted product, or if the manufacturing address, model/specification, or IFU version is inconsistent with test reports, a company may be asked for supplementary explanations even if it has prepared a large volume of documents.

Before submission, companies should establish an evidence consistency checklist that maps product name, model/specification, intended use, applicable standards, test report numbers, clinical evaluation conclusions, risk management version, label/IFU version, and quality system certificate item by item. This action appears basic, but it can significantly reduce the probability of deficiency letters, especially for projects involving simultaneous submissions in multiple GHWP member states or multiple product families.

Localization Conversion and Agent Responsibilities

Target-market registration projects usually involve arrangements for a local agent, authorized representative, importer, or registration holder. Companies need to confirm in advance whether the local partner is only responsible for submitting documents or also for regulatory communication, certificate maintenance, post-market event reporting, change applications, and renewal reminders. Different responsibility boundaries directly affect certificate control and subsequent market stability.

Labels, IFU, and authorization documents cannot simply be translated. Companies should verify local language requirements, boundaries of product claims, warnings, storage and transport conditions, UDI or traceability requirements, importer information, authorized representative information, and after-sales contact information. For companies that already have CE, FDA, NMPA, or other market documents, the focus of localization conversion is to transform reusable evidence into a submission structure acceptable to the target country, rather than writing an isolated set of documents.

Post-Market Maintenance and Long-Term Planning

Registration completion does not mean compliance work is finished. Companies also need to maintain certificate validity, change records, distributor authorizations, complaint handling, adverse event reporting, recall processes, label versions, and regulatory update records. Many companies invest heavily in obtaining certificates but neglect post-market maintenance. Later, once there is a manufacturing address change, model expansion, IFU update, or agent replacement, certificates and market sales can easily become disconnected.

AIMEILI recommends that companies manage this issue within an annual international registration plan: first clarify target-market priorities, then establish a reusable document package and country gap list, and finally schedule submission, deficiency response, post-market maintenance, and renewal milestones. The value is not only improving registration efficiency in a single country, but also helping the company build replicable overseas compliance capability and reduce the cost of starting from zero each time it enters a new market.

Continue Reading

• Previous: Why Is the Saudi Medical Device Registration Cycle Extended?
• Next: How Is Post-Market Surveillance Conducted for Saudi Medical Device Registration?

Recommended Reading

• What Are the Risk Management Documentation Requirements for Philippines Medical Device Registration?
• How Should Performance Verification Documentation Be Prepared for Philippines Medical Device Registration?
• What Should Be Done If Quality System Evidence Is Inconsistent for Philippines Medical Device Registration?
• How Should Registration Documentation Be Prepared for Singapore Medical Device Registration?
• How Should Product Classification Be Determined for Singapore Medical Device Registration?
• How Should Technical Documentation Be Organized for Singapore Medical Device Registration?

Return to FAQ Center

News and Information

Contact AIMEILI

Content Review and Application Boundary

Content author: AIMEILI Regulatory Editorial Team

Professional review: AIMEILI Medical Device International Registration Project Team

Source principle: Priority is given to official regulatory authorities, international organizations, standards organizations, and publicly available regulatory information; industry media and project experience are used only as auxiliary judgment.

Application boundary: This article is for preliminary understanding, documentation preparation, and project planning. It does not replace the formal requirements, testing conclusions, or legal advice of the target country regulator.